Long-Acting Injectable Risperidone in the Treatment of Schizophrenia

Inclusion Criteria

• •1. Age 18 years or older.
• •2. Diagnosed with schizophrenia or schizoaffective disorder by the Structured Clinical Interview for Diagnosis (SCID) (Spitzer and First et al., 1996).
• •3. Patients should
• •1. have been hospitalized in the two years before study entry on a psychiatric inpatient unit, or
• •2. document explicit current evidence of increased use of outpatient services such as additional visits, day treatment or non-hospital residential treatment, increased dosage of medications or addition of concomitant psychotropic medications.
• •The b criterion will promptly be adjudicated by the study chairmen on a case-by case basis to insure credibility.
• •4. .Adequate transportation is available and the participant lives within a travel time of less than 1.5 hours, allowing attendance at all scheduled visits.
• •5. Use of an acceptable method of birth control by female patients who have a possibility of becoming pregnant (safety concerns).
• •6. Able to demonstrate decisional capacity in order to give informed consent as assessed by the MacArthur Competence Assessment Tool (MacCAT) (Appelbaum and Grisso, 1996). Guardian consent is acceptable where applicable.
• •7. Dually diagnosed patients with both schizophrenia and addictive disorders would be included in this study but should not be in need of acute detoxification for physiologic substance dependence (excluding nicotine) in the past 30 days.